The estimated Net Worth of Robert Hadfield is at least $1.36 Million dollars as of 8 January 2021. Mr. Hadfield owns over 26,500 units of Alaunos Therapeutics Inc stock worth over $115,988 and over the last 9 years he sold ZIOP stock worth over $159,361. In addition, he makes $1,081,820 as Executive Vice President, Chief Compliance Officer, General Counsel und Secretary at Alaunos Therapeutics Inc.
Sign up
Mr. Hadfield ZIOP stock SEC Form 4 insiders trading
Robert has made over 2 trades of the Alaunos Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 26,500 units of ZIOP stock worth $82,680 on 8 January 2021.
The largest trade he's ever made was selling 26,500 units of Alaunos Therapeutics Inc stock on 8 January 2021 worth over $82,680. On average, Robert trades about 4,817 units every 41 days since 2016. As of 8 January 2021 he still owns at least 133,319 units of Alaunos Therapeutics Inc stock.
You can see the complete history of Mr. Hadfield stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Hadfield biography
Robert Hadfield J.D. serves as Executive Vice President, Chief Compliance Officer, General Counsel, Secretary of the Company. Mr. Hadfield has served as our Executive Vice President, General Counsel, Secretary and Chief Compliance Officer since December 2018 and as our General Counsel and Secretary since April 2018. Previously, Mr. Hadfield was the General Counsel of Longwood Fund, a health care venture capital fund, from November 2017 until April 2018. Prior to Longwood Fund, Mr. Hadfield was the General Counsel of Flex Pharma, Inc. from April 2014 until November 2017. Mr. Hadfield was an attorney in the business department of Cooley LLP from August 2007 to August 2011 and then from April 2012 to April 2014. From August 2011 to April 2012, Mr. Hadfield served as the Corporate Counsel at Kiva Systems, Inc. prior to its acquisition by Amazon.com, Inc. Mr. Hadfield began his career as a financial analyst in the health care investment banking group of Cowen Inc. Mr. Hadfield holds a B.S. degree in Finance from Providence College and a J.D. from the Georgetown University Law Center.
What is the salary of Robert Hadfield?
As the Executive Vice President, Chief Compliance Officer, General Counsel und Secretary of Alaunos Therapeutics Inc, the total compensation of Robert Hadfield at Alaunos Therapeutics Inc is $1,081,820. There are 2 executives at Alaunos Therapeutics Inc getting paid more, with Laurence Cooper having the highest compensation of $3,317,570.
How old is Robert Hadfield?
Robert Hadfield is 42, he's been the Executive Vice President, Chief Compliance Officer, General Counsel und Secretary of Alaunos Therapeutics Inc since 2018. There are 17 older and no younger executives at Alaunos Therapeutics Inc. The oldest executive at Alaunos Therapeutics Inc is J. Kevin Buchi, 65, who is the Director.
What's Robert Hadfield's mailing address?
Robert's mailing address filed with the SEC is C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON, MA, 02129.
Insiders trading at Alaunos Therapeutics Inc
Over the last 19 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk und Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.
What does Alaunos Therapeutics Inc do?
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
What does Alaunos Therapeutics Inc's logo look like?
Complete history of Mr. Hadfield stock trades at Alaunos Therapeutics Inc
Alaunos Therapeutics Inc executives and stock owners
Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Laurence Cooper,
Chief Executive Officer, Director -
Satyavrat Shukla,
Chief Financial Officer -
Robert Hadfield,
Executive Vice President, Chief Compliance Officer, General Counsel, Secretary -
Kevin Lafond,
Senior Vice President - Finance, Chief Accounting Officer, Treasurer -
Heidi Hagen,
Independent Director -
Dr. Eleanor de Groot Ph.D.,
Exec. VP of Operations -
Christopher Bowden,
Independent Director -
Scott Tarriff,
Independent Chairman of the Board -
Dr. Raffaele Baffa M.D., Ph.D.,
Chief Medical Officer and Exec. VP of R&D -
Elan Ezickson,
Independent Director -
Zuie-Chin Huang M.B.A.,
Exec. Chairman -
Mary Thistle,
Independent Director -
Raffaele Baffa,
Chief Medical Officer -
Christopher Taylor,
Vice President, Investor Relations and Corporate Communications -
James Huang,
Director -
J. Kevin Buchi,
Director -
Lynn Ferrucci,
Executive Vice President of Human Resources, Facilities, Administration and IT -
Eleanor De Groot,
Executive Vice President, General Manager, Cell Therapy -
Jill Buck,
Executive Vice President, General Manager, Gene Therapy -
Dr. Drew Deniger,
Head of TCR-T Cell Therapy Program -
Dr. David M. Mauney M.D.,
Consultant -
Melinda Lackey,
Sr. VP of Legal -
Michael Wong,
VP of Fin. & Principal Accounting Officer -
Timothy M. Cunningham CPA, M.B.A.,
Interim CFO & Principal Financial Officer -
Kevin S. Boyle Sr.,
CEO & Director -
James Anthony Cannon,
Director -
Randal Jintrexon Corp Kirk,
-
Murray Brennan,
Director -
Wyche Fowler,
Director -
Randal J Kirk,
Director -
Caesar J Belbel,
COO, CLO, and Secretary -
Michael Weiser,
Director -
Francois Lebel,
Executive Vice President R&D -
David M Md Mauney,
President -
Douglas W. Pagan,
Director -
Scott Braunstein,
Director -
Hagop Youssoufian,
Executive VP, CMO -
Timothy Mcinerney,
Director -
Jonathan Lewis,
CEO -
Jason Amello,
Executive Vice President & CFO -
Richard E Bagley,
President, COO & Treasurer -
George B Abercrombie,
Director -
Robert Peter Gale,
Senior V.P. of Research -
Lindsay A Md Rosenwald,
10% owner -
Woodlands Health Ventures F...,
10% owner -
Gary S Fragin,
Director -
Sath Shukla,
EVP, Chief Financial Officer -
Jaime Vieser,
Director -
Holger Weis,
Director -
Robert W Postma,
Director -
Kevin S. Sr. Boyle,
Chief Executive Officer -
Melinda Lackey,
Senior Vice President, Legal